Papers: 10.1371/journal.pone.0184423

https://doi.org/10.1371/journal.pone.0184423

Cabozantinib versus everolimus, nivolumab, axitinib, sorafenib and best supportive care: A network meta-analysis of progression-free survival and overall survival in second line treatment of advanced renal cell carcinoma

Cited by: 41
Author(s): Billy Amzal, Shuai Fu, Jie Meng, J. Lister, Hélène Karcher
Published: about 9 years ago

Software Mentions 2